You are an integral part of the solution.

None of us can defeat cancer alone. Together, our combined individual contributions can be put together to advance against cancer effectively by identifying the key researchers and their epigenetic research to eradicate it at its source.

Learn More
You are an integral part of the solution.

None of us can defeat cancer alone. Together, our combined individual contributions can be put together to advance against cancer effectively by identifying the key researchers and their epigenetic research to eradicate it at its source.

Learn More

Our achievements through collaboration:

Learn More
Our achievements through collaboration:

Leukemia

We partnered with researchers from the Shanghai Institute of Hematology to develop the first successful targeted differentiation therapy for acute promyelocytic leukemia (APL) with all-trans-retinoic acid and arsenic trioxide which increased the disease’s five-year survival rate from 25% to 95%.

Liver Cancer

We pioneered the use of the first successful liver cancer drug treatment through an international consortium led by Mount Sinai.

Breast Cancer

We created a novel combination of two existing cancer therapies for the treatment of hormone-resistant breast cancer, producing a new clinical trial at several New York hospitals led by Mount Sinai.

Pediatric Cancer

We brought together scientists from the Harvard Cancer Center and the Dana-Farber Cancer Institute to develop a targeted therapy for a rare childhood cancer, which is currently in clinical trials.

Lung Cancer

We advanced the paradigm of treatment for lung cancer by adding targeted drugs to chemotherapy through a collaboration between Dartmouth and Mount Sinai.

Leukemia

We partnered with researchers from the Shanghai Institute of Hematology to develop the first successful targeted differentiation therapy for acute promyelocytic leukemia (APL) with all-trans-retinoic acid and arsenic trioxide which increased the disease’s five-year survival rate from 25% to 95%.

Liver Cancer

We pioneered the use of the first successful liver cancer drug treatment through an international consortium led by Mount Sinai.

Breast Cancer

We created a novel combination of two existing cancer therapies for the treatment of hormone-resistant breast cancer, producing a new clinical trial at several New York hospitals led by Mount Sinai.

Pediatric Cancer

We brought together scientists from the Harvard Cancer Center and the Dana-Farber Cancer Institute to develop a targeted therapy for a rare childhood cancer, which is currently in clinical trials.

Lung Cancer

We advanced the paradigm of treatment for lung cancer by adding targeted drugs to chemotherapy through a collaboration between Dartmouth and Mount Sinai.
SWIPE

Our Progress: